Multiple Sclerosis

A meta-analysis of 3 case-controlled MS studies showed an association between susceptibility to multiple sclerosis (MS) and the vitamin D pathway.

A national single-center observational retrospective study reveals the long-term benefits of hematopoietic stem cell transplantation in the treatment of multiple sclerosis (MS).

A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients.

A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.

A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS).

A cross-sectional analysis evaluated a myriad of socioeconomic and demographic factors that drive stigma experienced by patients with multiple sclerosis (MS).

Exposure to tobacco smoke in utero has the potential to make offspring more vulnerable to developing multiple sclerosis (MS).

More research is necessary to understand cerebral oxygen consumption as a predictive biomarker for brain atrophy in multiple sclerosis (MS); however, this study found that mitochondrial dysfunction could have a role in the underlying pathophysiology of MS.

A prospective analysis suggested that those with pediatric-onset multiple sclerosis (MS) who experienced earlier disease-modifying treatment initiation may be less vulnerable to disease progression.

A population-based study drew a possible connection between gastrointestinal (GI) symptoms and the multiple sclerosis (MS) prodrome.

Misdiagnoses of multiple sclerosis (MS) represent one of the prominent challenges in MS for patients, clinicians, and researchers. A variety of factors influence misdiagnosis, including testing deficiencies, copycat diseases, and more.

A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.

A recent meta-analysis revealed significant differences in characteristic between patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS), highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.

This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.

Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.

The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.

A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS).

The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

In an observational cohort study, factors such as education, income, and marital status correlated with MS severity outcomes.

Researchers conducted a cohort study that suggests oral N-acetylglucosamine treatment can hinder neurodegeneration and inflammation associated with multiple sclerosis (MS).

Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis (MS) compared with those with NMOSD, although the difference was not statistically significant.